Structural basis for human sterol isomerase in cholesterol biosynthesis and multidrug recognition.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31165728.
- Also identified by DOI 10.1038/s41467-019-10279-w and PMC identifier 6549186.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
3-β-hydroxysteroid-Δ<sup>8</sup>, Δ<sup>7</sup>-isomerase, known as Emopamil-Binding Protein (EBP), is an endoplasmic reticulum membrane protein involved in cholesterol biosynthesis, autophagy, oligodendrocyte formation. The mutation on EBP can cause Conradi-Hunermann syndrome, an inborn error. Interestingly, EBP binds an abundance of structurally diverse pharmacologically active compounds, causing drug resistance. Here, we report two crystal structures of human EBP, one in complex with the anti-breast cancer drug tamoxifen and the other in complex with the cholesterol biosynthesis inhibitor U18666A. EBP adopts an unreported fold involving five transmembrane-helices (TMs) that creates a membrane cavity presenting a pharmacological binding site that accommodates multiple different ligands. The compounds exploit their positively-charged amine group to mimic the carbocationic sterol intermediate. Mutagenesis studies on specific residues abolish the isomerase activity and decrease the multidrug binding capacity. This work reveals the catalytic mechanism of EBP-mediated isomerization in cholesterol biosynthesis and how this protein may act as a multi-drug binder.
Medical subject headings
- Androstenes
- Anticholesteremic Agents
- Estrogen Antagonists
- Steroid Isomerases
- Tamoxifen